Amivantamab binds EGFR on target cells and its IgG1 Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells) to induce antibody-dependent cellular cytotoxicity (ADCC), leading to target-cell lysis; it also blocks signaling but killing is via ADCC.